Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC33880101863;101864;101865 chr2:178534977;178534976;178534975chr2:179399704;179399703;179399702
N2AB3223996940;96941;96942 chr2:178534977;178534976;178534975chr2:179399704;179399703;179399702
N2A3131294159;94160;94161 chr2:178534977;178534976;178534975chr2:179399704;179399703;179399702
N2B2481574668;74669;74670 chr2:178534977;178534976;178534975chr2:179399704;179399703;179399702
Novex-12494075043;75044;75045 chr2:178534977;178534976;178534975chr2:179399704;179399703;179399702
Novex-22500775244;75245;75246 chr2:178534977;178534976;178534975chr2:179399704;179399703;179399702
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: E
  • RefSeq wild type transcript codon: GAA
  • RefSeq wild type template codon: CTT
  • Domain: Kinase-1
  • Domain position: 68
  • Q(SASA): 0.143
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
E/A rs1690780313 None None N None 0.512 0.313818047136 gnomAD-4.0.0 1.36875E-06 None None None None N None 0 0 None 0 0 None 0 0 1.79897E-06 0 0
E/Q None None None N None 0.308 0.331365685468 gnomAD-4.0.0 1.20032E-06 None None None None N None 0 0 None 0 0 None 0 0 1.3125E-06 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
E/A 0.6154 likely_pathogenic 0.5653 pathogenic 0.046 Stabilizing None None None None N 0.480144126 None None N
E/C 0.9699 likely_pathogenic 0.9678 pathogenic -0.12 Destabilizing None None None None None None None None N
E/D 0.4823 ambiguous 0.4486 ambiguous -1.167 Destabilizing None None None None N 0.4199196 None None N
E/F 0.9838 likely_pathogenic 0.9784 pathogenic 0.943 Stabilizing None None None None None None None None N
E/G 0.5937 likely_pathogenic 0.5483 ambiguous -0.365 Destabilizing None None None None N 0.453549384 None None N
E/H 0.89 likely_pathogenic 0.8688 pathogenic 0.933 Stabilizing None None None None None None None None N
E/I 0.9375 likely_pathogenic 0.9238 pathogenic 1.172 Stabilizing None None None None None None None None N
E/K 0.6112 likely_pathogenic 0.5647 pathogenic 0.111 Stabilizing None None None None N 0.499962038 None None N
E/L 0.9349 likely_pathogenic 0.922 pathogenic 1.172 Stabilizing None None None None None None None None N
E/M 0.9347 likely_pathogenic 0.9276 pathogenic 1.275 Stabilizing None None None None None None None None N
E/N 0.8143 likely_pathogenic 0.7735 pathogenic -0.754 Destabilizing None None None None None None None None N
E/P 0.9789 likely_pathogenic 0.979 pathogenic 0.82 Stabilizing None None None None None None None None N
E/Q 0.4044 ambiguous 0.3784 ambiguous -0.505 Destabilizing None None None None N 0.505522573 None None N
E/R 0.724 likely_pathogenic 0.6775 pathogenic 0.418 Stabilizing None None None None None None None None N
E/S 0.6687 likely_pathogenic 0.6238 pathogenic -1.008 Destabilizing None None None None None None None None N
E/T 0.7796 likely_pathogenic 0.7507 pathogenic -0.622 Destabilizing None None None None None None None None N
E/V 0.8285 likely_pathogenic 0.8062 pathogenic 0.82 Stabilizing None None None None N 0.47272364 None None N
E/W 0.9945 likely_pathogenic 0.9933 pathogenic 1.164 Stabilizing None None None None None None None None N
E/Y 0.9655 likely_pathogenic 0.9578 pathogenic 1.256 Stabilizing None None None None None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.